A benefit-risk assessment of extended-release oxybutynin.
about
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).Management of mixed urinary incontinence.
P2860
A benefit-risk assessment of extended-release oxybutynin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A benefit-risk assessment of extended-release oxybutynin.
@ast
A benefit-risk assessment of extended-release oxybutynin.
@en
A benefit-risk assessment of extended-release oxybutynin.
@nl
type
label
A benefit-risk assessment of extended-release oxybutynin.
@ast
A benefit-risk assessment of extended-release oxybutynin.
@en
A benefit-risk assessment of extended-release oxybutynin.
@nl
prefLabel
A benefit-risk assessment of extended-release oxybutynin.
@ast
A benefit-risk assessment of extended-release oxybutynin.
@en
A benefit-risk assessment of extended-release oxybutynin.
@nl
P1433
P1476
A benefit-risk assessment of extended-release oxybutynin.
@en
P2093
Martin C Michel
P304
P356
10.2165/00002018-200225120-00004
P577
2002-01-01T00:00:00Z
P6179
1004006501